Evidence for cross-hemispheric preconditioning in experimental Parkinson's disease.

Brain Struct Funct

Division of Pharmaceutical Sciences, Duquesne University, 407 Mellon Hall, 600 Forbes Ave, Pittsburgh, PA, 15282, USA.

Published: April 2018

Dopamine loss and motor deficits in Parkinson's disease typically commence unilaterally and remain asymmetric for many years, raising the possibility that endogenous defenses slow the cross-hemispheric transmission of pathology. It is well-established that the biological response to subtoxic stress prepares cells to survive subsequent toxic challenges, a phenomenon known as preconditioning, tolerance, or stress adaptation. Here we demonstrate that unilateral striatal infusions of the oxidative toxicant 6-hydroxydopamine (6-OHDA) precondition the contralateral nigrostriatal pathway against the toxicity of a second 6-OHDA infusion in the opposite hemisphere. 6-OHDA-induced loss of dopaminergic terminals in the contralateral striatum was ablated by cross-hemispheric preconditioning, as shown by two independent markers of the dopaminergic phenotype, each measured by two blinded observers. Similarly, loss of dopaminergic somata in the contralateral substantia nigra was also abolished, according to two blinded measurements. Motor asymmetries in floor landings, forelimb contacts with a wall, and spontaneous turning behavior were consistent with these histological observations. Unilateral 6-OHDA infusions increased phosphorylation of the kinase ERK2 and expression of the antioxidant enzyme CuZn superoxide dismutase in both striata, consistent with our previous mechanistic work showing that these two proteins mediate preconditioning in dopaminergic cells. These findings support the existence of cross-hemispheric preconditioning in Parkinson's disease and suggest that dopaminergic neurons mount impressive natural defenses, despite their reputation as being vulnerable to oxidative injury. If these results generalize to humans, Parkinson's pathology may progress slowly and asymmetrically because exposure to a disease-precipitating insult induces bilateral upregulation of endogenous defenses and elicits cross-hemispheric preconditioning.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11061878PMC
http://dx.doi.org/10.1007/s00429-017-1552-6DOI Listing

Publication Analysis

Top Keywords

cross-hemispheric preconditioning
16
parkinson's disease
12
endogenous defenses
8
loss dopaminergic
8
preconditioning
6
dopaminergic
5
evidence cross-hemispheric
4
preconditioning experimental
4
parkinson's
4
experimental parkinson's
4

Similar Publications

Conditioning Against the Pathology of Parkinson's disease.

Cond Med

April 2018

Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA 15282, USA.

Parkinson's disease is delayed in clinical onset, asymmetric in initial appearance, and slow in progression. One explanation for these characteristics may be a boost in natural defenses after early exposure to mild cellular stress. As the patient ages and resilience recedes, however, stress levels may become sufficiently high that toxic cellular responses can no longer be curbed, culminating in inverted U-shaped stress-response curves as a function of disease duration.

View Article and Find Full Text PDF

Evidence for cross-hemispheric preconditioning in experimental Parkinson's disease.

Brain Struct Funct

April 2018

Division of Pharmaceutical Sciences, Duquesne University, 407 Mellon Hall, 600 Forbes Ave, Pittsburgh, PA, 15282, USA.

Dopamine loss and motor deficits in Parkinson's disease typically commence unilaterally and remain asymmetric for many years, raising the possibility that endogenous defenses slow the cross-hemispheric transmission of pathology. It is well-established that the biological response to subtoxic stress prepares cells to survive subsequent toxic challenges, a phenomenon known as preconditioning, tolerance, or stress adaptation. Here we demonstrate that unilateral striatal infusions of the oxidative toxicant 6-hydroxydopamine (6-OHDA) precondition the contralateral nigrostriatal pathway against the toxicity of a second 6-OHDA infusion in the opposite hemisphere.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!